We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+16.12%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.01B
AUM Growth
-$101M
Cap. Flow
-$291M
Cap. Flow %
-14.52%
Top 10 Hldgs %
62.57%
Holding
41
New
5
Increased
9
Reduced
5
Closed
13

Top Buys

Rank Stock Value
1
DVA icon
DaVita
DVA
+$73.7M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$61.7M
3
BMY icon
Bristol-Myers Squibb
BMY
+$54.8M
4
BIIB icon
Biogen
BIIB
+$47.2M
5
AGN
Allergan plc
AGN
+$43.5M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$208M
2
MCK icon
McKesson
MCK
+$96.7M
3
CELG
Celgene Corp
CELG
+$96.1M
4
GSK icon
GSK
GSK
+$76.4M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$43.7M

Sector Composition

Rank Sector Weight
1 Healthcare 80.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$771B
$282M 14.07%
+1,000,000
New +$272M
AGN
2
DELISTED
Allergan plc
AGN
$190M 9.48%
1,300,000
+300,000
+30% +$43.5M
VTRS icon
3
Viatris
VTRS
$20.8B
$163M 8.12%
5,750,000
+750,000
+15% +$21.9M
PRGO icon
4
Perrigo
PRGO
$1.44B
$101M 5.04%
2,100,000
-100,000
-5% -$4.68M
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
$95.3M 4.75%
1,800,000
-450,000
-20% -$22.1M
BIIB icon
6
Biogen
BIIB
$30.9B
$94.6M 4.71%
400,000
+150,000
+60% +$47.2M
UHS icon
7
Universal Health Services
UHS
$10.2B
$87M 4.33%
650,000
-250,000
-28% -$32.9M
DVA icon
8
DaVita
DVA
$15.5B
$81.4M 4.06%
1,500,000
+1,332,472
+795% +$73.7M
ALXN
9
DELISTED
Alexion Pharmaceuticals
ALXN
$81.1M 4.04%
600,000
– –
ATRA icon
10
Atara Biotherapeutics
ATRA
$72.6M
$79.5M 3.96%
80,000
+4,000
+5% +$3.72M
BKD icon
11
Brookdale Senior Living
BKD
$3.55B
$72.4M 3.61%
11,000,000
+3,500,000
+47% +$25.7M
MDCO
12
DELISTED
Medicines Co
MDCO
$69.1M 3.44%
2,471,523
+471,523
+24% +$11.1M
NKTR icon
13
Nektar Therapeutics
NKTR
$2.39B
$67.2M 3.35%
133,333
– –
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.64B
$59.6M 2.97%
500,000
+150,000
+43% +$19.3M
MNTA
15
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$58.1M 2.9%
4,000,000
– –
TEVA icon
16
Teva Pharmaceuticals
TEVA
$40.4B
$54.9M 2.73%
+3,500,000
New +$61.7M
BMY icon
17
Bristol-Myers Squibb
BMY
$129B
$52.5M 2.61%
+1,100,000
New +$54.8M
ASND icon
18
Ascendis Pharma A/S
ASND
$16.5B
$50.6M 2.52%
+430,000
New +$37.7M
THC icon
19
Tenet Healthcare
THC
$22.2B
$50.5M 2.51%
1,750,000
-1,500,000
-46% -$37M
NUVA
20
DELISTED
NuVasive, Inc.
NUVA
$42.6M 2.12%
+750,000
New +$39.9M
THOR
21
DELISTED
Synthorx, Inc. Common Stock
THOR
$37.9M 1.89%
1,862,116
– –
CLVS
22
DELISTED
Clovis Oncology, Inc.
CLVS
$37.2M 1.86%
1,500,000
-1,300,000
-46% -$32.6M
ZYME icon
23
Zymeworks
ZYME
$1.62B
$35M 1.75%
2,166,000
– –
AMAG
24
DELISTED
AMAG Pharmaceuticals
AMAG
$34.1M 1.7%
2,650,000
– –
EGRX
25
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$14.7M 0.73%
291,600
– –
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Camber Capital Management held 41 positions worth $2.01B, down 4.8% from $2.11B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Camber Capital Management withdrew a net $291M in Q1 2019, closing 13 positions and reducing 5 holdings. Its most notable exit was TESARO, Inc., an estimated $208M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 84% a quarter earlier.

Against the trend, Camber Capital Management opened a new position in Teva Pharmaceuticals worth $54.9M.

  • Camber Capital Management's largest Q1 2019 buy was Teva Pharmaceuticals: 3,500,000 shares worth $54.9M.
  • Camber Capital Management added most to DaVita in Q1 2019, an estimated $73.7M increase.
  • Camber Capital Management's biggest Q1 2019 reduction was Tenet Healthcare, cutting an estimated $37M.
  • Camber Capital Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $208M.
  • Camber Capital Management's ten largest holdings make up 63% of its $2.01B portfolio in Q1 2019.
  • Camber Capital Management opened 5 new positions and closed 13 in Q1 2019.
  • Camber Capital Management's portfolio value fell 4.8% quarter-over-quarter to $2.01B.

Based on Camber Capital Management's 13F filing for Q1 2019, filed 15 May 2019.